Picture of Hisamitsu Pharmaceutical Co logo

4530 — Hisamitsu Pharmaceutical Co News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

Table: Hisamitsu -2015/16 group results

Apr 8 (Reuters)-  
          Hisamitsu Pharmaceutical Co Inc  
          CONSOLIDATED FINANCIAL HIGHLIGHTS  
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to       NEXT    
                Feb 29, 2016    Feb 28, 2015   Feb 28, 2017     YEAR      
                   LATEST         YEAR-AGO        COMPANY      COMPANY    
                   RESULTS         RESULTS       FORECAST    H1 FORECAST  
  Sales            161.85          156.74         155.00        79.80     
                 (+3.3 pct)      (+4.1 pct)     (-4.2 pct)    (-3.2 pct)  
  Operating         27.73           20.53          28.00        11.60     
                 (+35.1 pct)     (+7.3 pct)     (+1.0 pct)   (-20.1 pct)  
  Recurring         28.01           28.49          29.00        12.20     
                 (-1.7 pct)      (-1.5 pct)     (+3.5 pct)   (-16.6 pct)  
  Net               17.78           18.78                                 
                 (-5.3 pct)      (-12.0 pct)                              
  Net                                              19.40         8.70     
                                                (+9.1 pct)    (-7.2 pct)  
  EPS            208.81 yen      219.28 yen     227.79 yen    102.15 yen  
  EPS Diluted    208.76 yen                                               
  Ann Div         81.00 yen       80.00 yen      81.00 yen                
  -Q2 Div         40.00 yen       37.50 yen      40.50 yen                
  -Q4 Div         41.00 yen       42.50 yen      40.50 yen                
   
  NOTE - Hisamitsu Pharmaceutical Co Inc. 
  *Second Net profit row denotes profit attributable to owners ofthe parent  
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4530.T 
  ((Tokyo Headline News Desk +813 6441 1812))

Recent news on Hisamitsu Pharmaceutical Co

See all news